Leerink Partnrs Brokers Raise Earnings Estimates for INSP

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Equities researchers at Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for Inspire Medical Systems in a research note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of $0.77 per share for the quarter, up from their previous forecast of $0.72. The consensus estimate for Inspire Medical Systems' current full-year earnings is $0.75 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems' Q4 2025 earnings at $1.12 EPS and FY2028 earnings at $5.77 EPS.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.54. Inspire Medical Systems had a return on equity of 5.51% and a net margin of 4.37%. The firm had revenue of $203.20 million for the quarter, compared to analysts' expectations of $197.59 million. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. The company's quarterly revenue was up 32.6% on a year-over-year basis.

Several other equities analysts have also issued reports on the company. Robert W. Baird lifted their target price on Inspire Medical Systems from $240.00 to $252.00 and gave the company an "outperform" rating in a research note on Tuesday. Piper Sandler restated an "overweight" rating and set a $260.00 price target (up previously from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday. Leerink Partners lifted their price objective on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the stock a "market perform" rating in a research note on Tuesday, September 10th. KeyCorp cut their target price on Inspire Medical Systems from $278.00 to $236.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 7th. Finally, Morgan Stanley reduced their target price on Inspire Medical Systems from $250.00 to $210.00 and set an "overweight" rating for the company in a research note on Monday, July 15th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Inspire Medical Systems has an average rating of "Moderate Buy" and an average target price of $227.75.

Inspire Medical Systems Trading Up 6.3 %

Shares of NYSE INSP traded up $12.63 during trading hours on Wednesday, reaching $211.63. The stock had a trading volume of 1,043,542 shares, compared to its average volume of 397,234. The business's fifty day moving average price is $201.94 and its two-hundred day moving average price is $179.94. The firm has a market cap of $6.31 billion, a price-to-earnings ratio of 197.79 and a beta of 1.36. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40.

Hedge Funds Weigh In On Inspire Medical Systems

A number of large investors have recently made changes to their positions in the stock. SouthState Corp purchased a new stake in Inspire Medical Systems in the 2nd quarter valued at approximately $27,000. Farther Finance Advisors LLC lifted its holdings in Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock valued at $32,000 after purchasing an additional 139 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company's stock worth $38,000 after purchasing an additional 151 shares during the last quarter. Quarry LP grew its holdings in shares of Inspire Medical Systems by 105.4% during the second quarter. Quarry LP now owns 343 shares of the company's stock worth $46,000 after buying an additional 176 shares in the last quarter. Finally, Daiwa Securities Group Inc. acquired a new position in shares of Inspire Medical Systems in the second quarter valued at approximately $53,000. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the sale, the director now owns 23,140 shares in the company, valued at $5,090,800. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the transaction, the director now directly owns 23,140 shares of the company's stock, valued at approximately $5,090,800. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $188.55, for a total value of $916,541.55. Following the completion of the transaction, the insider now owns 3,056 shares in the company, valued at $576,208.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,692 shares of company stock valued at $1,099,207 over the last 90 days. 4.10% of the stock is owned by insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.